Overview
Investor Relations Overview
Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases.
Corporate Presentation – September 2021
Recent News
- Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
- Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
- Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering